BACKGROUND: Nasopharyngeal Angiofibroma is a rare neoplasm in the sphenopalatine foramen. This tumour is histologically benign, but clinically malignant because it can erode the bone and surrounding structures, such as the pterygopalatine fossa, paranasal sinuses, and nasal cavity. It is a highly vascular tumour, sometimes from multiple Feeding arteries, and tends to bleed easily.
Introduction
Nasopharyngeal Angiofibroma (NA) is a rare, benign and highly vascular tumour originating in the sphenopalatine foramen, and may extend to the pterygopalatine fossa, paranasal sinuses and nasal cavity [1] . They accounted for 0.05% of all head and neck tumours and reported to be 1 per 5,000-60,000 Ear Nose Throat (ENT) patients in the United States. NA occurs exclusively in men. NA generally occurs in the second decade of life between 7-19 years old and rarely occurs at the age of more than 25 years. Randowski et al., classified Nasopharyngeal Angiofibroma into three stages, based on the expansion of the tumour (Table1) [2] , [3] , [4] . Limited to the nasal cavity and / or nasopharyngeal area IB Same as stage I with expansion to one or more paranasal sinuses IIA Minimal expansion to the sphenopalatine foramen includes a minimal portion of the medial part of the pterygopalatine fossa IIB
The tumour occupies the entire sphenopalatine fossa space, forces the posterior wall of the maxilla forward, shifts laterally or anteriorly from the maxillary artery branch, superior expansion may be present, orbital bone erosion IIC Extension to the pterygopalatine fissure towards the cheek and infratemporal fossa or towards the posterior pterygoid plate IIIA Erosion of the skull base (cranial base) with minimal expansion towards the intracranial IIIB Erosion of the skull base (cranial base) with extensive expansion in the intracranial direction with or without involving the cavernous sinus
In this article, we reported our first five institutional cases of nasopharyngeal angiofibroma referred from the ENT department, which is four cases in children and a rare case in an elderly patient. The diagnoses were made by history taking, physical examination and radiological imaging with Cerebral and carotid Multiple Slice Computed Tomography (MSCT) angiography. All patients underwent preoperative Digital Subtraction Angiography (DSA) to determine the arterial Feeding of the tumour, followed by endovascular embolisation using polyvinyl alcohol (PVA) foam particles. Clinical manifestations including the symptoms and signs of each case will be discussed individually, along with the description of pre and post-procedural outcome.
Case Series

Case 1
A 13-year-old boy presented with nasal obstruction and breathing difficulties experienced for 1 year earlier, occurring slowly and then worsening in the last 3 months. He also had epistaxis in his right nasal cavity and felt pain in his right ear. Physical examination revealed a lump in the right nasal cavity. Physical examination revealed a lump in the right nasal cavity. The result of laboratory tests, Hemoglobin (Hb) at admission was 10.5 g/dl, and postoperative Hb was 10.3 g/dl. MSCT Angiography of cerebral and carotid showed an isodense mass (30.47 HU) with intense contrast uptake. The mass was well-defined, with irregular edges covering the nasopharynx particularly at the right sphenopalatine foramen extending to the right nasal cavity, right maxillary sinus, sphenoid sinus bilateral and right ethmoidal, caused bowing of right maxillary and ethmoidal bones. It also pushed the nasal septum to the left. This patient was diagnosed with stage II right nasopharyngeal angiofibroma.
Cerebral DSA procedure was performed, and the catheter tip was navigated to the right common carotid artery (RCCA). RCCA injection revealed the Feeding artery, which was originated from the C4 segment of the right internal carotid artery (RICA) and the right internal maxillary artery, a branch of the right external carotid artery (RECA). Tumour embolisation was carried out using 300-500 microns polyvinyl alcohol (PVA) foam particles, at the right internal maxillary artery, until the tumour blush decreased. Feeding artery originating from the right internal carotid artery could not be embolized for they were small and could not be reached by the available microcatheter. The post-surgical diagnosis was nasopharyngeal angiofibroma. The amount of blood loss during surgery was ± 500 cc. The patient was discharged without complication on day 6 after the operation.
Case 2
A 16-year-old boy presented with left nasal obstruction in the past 4 months before admission, accompanied by epistaxis. His physical examination revealed a tumour, covering his left nasal cavity. The result of laboratory tests was as followed: Hb at admission was 11.8 g/dl, and Hb post-surgery was 7.8 g/dl. The result of MSCT Angiography of cerebral and carotid showed a centrifuging mass in the sphenopalatine canal area with a crowded vascular pattern that expanded and widened into the left maxillary sinus. The mass encroached the pterygomaxillary fossa and filled up most of the infratemporal space area. It extended into sphenoid and ethmoid sinuses as well as to the left side of the nasal cavity which narrowed the airway. No intracranial lesions were seen. The main Feeding artery was from the branch of the left internal maxillary artery.
He was diagnosed with Juvenile Nasopharyngeal Angiofibroma (JNA) with Feeding artery from an internal maxillary artery (Radkowsky Grade IIc) ( Table 1 ).
Cerebral DSA procedure through the left external carotid artery (LECA) injection showed a tumour blush that supplied by the left internal maxillary artery. Tumour embolisation was carried out using PVA foam particles 300-500 microns in the left internal maxillary artery until the tumour blush on the left side disappeared. Tumour resection was performed afterwards. The histopathological result showed proliferation of blood vessels containing erythrocytes, between connective tissue. This finding was well-matched with angiofibroma ( Figure 1 ). The patient was discharged 6 days after surgery without severe complications.
Figure 1: Histological features of angiofibroma. A) Visible erythrocyte between the proliferation of connective tissue (black arrow) 4 X magnification; B) Thin-walled vascular structure containing erythrocytes with a large layer of endothelium and fibrous component (blue arrow) 10 X magnification; C) Proliferation
of connective tissue with components of fibroblast cells, with the thin layer of endothelium, 40 X enlargement (staining of hematoxylin-eosin) https://www.id-press.eu/mjms/index
Case 3
A 16-year-old boy presented with epistaxis for 4 months before admission. The epistaxis gradually worsened during the last 2 months before admission. The complaint was accompanied by nasal congestion and headache. Physical examination revealed a tumor in the right nasal cavity. The result of Hb tests was 11.2 g/dl and 10.5 g/dl for preoperative and postoperative, respectively. The result of MSCT angiography of cerebral and carotid showed a heterogeneous mass that enhances avidly upon contrast administration (90 HU). The mass showed well-definite boundaries and regular edges which originated from the right side of the nasopharynx and compressed the airway. It did not destroy the surrounding bones nor infiltrate the intracranial tissues. The Feeding artery was the right internal maxillary artery. The nasopharyngeal mass was consistent with angiofibroma. Cerebral DSA procedure was performed, and injection through RECA showed tumour blush which was supplied by the right internal maxillary artery. The tumour was embolized using PVA particles 300-500 microns in the right internal maxillary artery until the tumour blush on the right side disappeared. Subsequently, resection surgery was performed with a total of ± 500 cc blood loss during the procedure. The tissue was sent to the histopathological laboratory, and the result was consistent with angiofibroma. The patient was treated for 5 days postoperatively and eventually got discharged.
Case 4
An 11-year-old boy visited the ENT outpatient clinic with his parents. The boy came with right nasal obstruction for 3 months before admission. Physical examination showed proptosis of the right eye and a tumour in the right nasal cavity ( Figure 2 ). Laboratory examination showed Hb results were 14.4 gr/dl and 14.5 g/dl for preoperative and postoperative, respectively.
Figure 2: A) Proptosis of the right eye; B) Tumor is visible through right cavum nasi
Noncontrast CT scan on paranasal sinuses showed expansive mass with heterogeneous density, well-defined boundary, and irregular edge. The size of the mass was 4.86 x 4.34 x 4.84 cm and tended to originate from the right maxillary sinus. The tumour infiltrated the right nasal cavity, sphenoid sinus, ethmoid sinus, right frontal sinus and pressed the nasal septum to the left and caused destruction of the lateral wall of the right maxillary sinus. The diagnosis was right sinonasal mass involving more than one paranasal sinuses ( Figure 3 ). The Feeding artery appeared to originate from the right internal maxillary artery ( Figure 5 ). The diagnosis was a sinonasal mass corresponding to sinonasal angiofibroma. Cerebral DSA procedure via RECA showed the presence of a tumour blush that was supplied by the right internal maxillary artery ( Figure 6, A and B ). Tumour embolisation was performed using PVA particles 300-500 microns through the right internal maxillary artery until the tumour blush on the right side disappeared (Figure 6 , C). After that, a nasopharyngeal angiofibroma resection surgery was performed with a total of ± 500 cc of blood loss during surgery. The tissue was sent to the histopathological anatomy laboratory with the results was following angiofibroma. The patient was treated for 5 days without complications and got discharged.
Figure 6: Digital Subtraction Angiography (DSA) cerebral, injection of the right external carotid artery (RECA). A) Pre embolization: There was a tumour blush with Feeding artery from the right internal maxillary artery (yellow arrow); B) Tumor blush was shown by blue arrow; C) Post embolization using PVA particle, in the right internal maxillary artery until the tumour blush on the right side was no longer visible (red arrow).
Case 5
A 61-years-old man came to the emergency department with unprovoked epistaxis for 5 months before admission. Laboratory examination showed the Hb results were 11.1 gr/dl and 10.5 g/dl for preoperative and postoperative, respectively. The results of Noncontrast CT scan on paranasal sinuses coronal view showed isodense mass (26 HU), with relatively firm boundaries, irregular edges, and without calcification. The tumour was from the right nasal cavity, eroded the right maxillary, extended to the right ethmoid sinus and pressed the nasal septum to contralateral. This finding was suggestive of right nasal cavity mass which extended into the right maxillary sinus and the right ethmoid sinus. Cerebral and carotid MSCT angiography showed a mass in the right nasal cavity, which was hypervascular and originated from the right maxillary artery. Cerebral DSA procedure was performed through the right internal carotid artery (RICA). Tumour blush was seen, originated from the right ophthalmic artery ( Figure 7, A and B) . Injection of the RECA also showed the feeding artery from the right internal maxillary artery ( Figure 7, A and B) . The tumour was embolized using PVA particles 300-500 microns until the tumour blush decreased (Figure 7 , C and D). The feeding artery originated from the right ophthalmic artery was not embolized because of the risk of causing blindness. The tumour blush was still visible but decreased to some extent ( Figure 7D ). After that, a nasopharyngeal angiofibroma resection surgery was performed with a total of ± 500 cc blood loss intraoperative. The tissue was sent to the histopathological test, and the result was angiofibroma. The patient was treated for 5 days without complications before finally discharged.
Pre-operative Endovascular Embolization and the Outcomes
All patients in this case series were treated with pre-operative embolisation before tumour resection. Tumour embolisation was performed using the endovascular trans-arterial technique, with PVA foam particles (William Cook Europe ApS, Denmark) as embolic material. The procedure was coded as Percutaneous Transcatheter Infusion Embolization (ICD-9-CM 99.29).
Cerebral DSA procedures were performed in case 1 and 4 with asepsis preparation and general anaesthesia. The right femoral artery was catheterised, using a 6F sheath (Merit Medical Systems Inc., South Jordan, USA, USA), and a 6F JR4 guide catheter (Terumo Corporation, Tokyo, Japan). The procedure was followed by tumour embolisation, using a 6F JR4 guide catheter (Terumo Corporation, Tokyo, Japan), 2.4F microcatheter (Terumo Corporation, Tokyo, Japan) and 1.4 micro guidewires (Terumo Corporation, Tokyo, Japan).
Cerebral DSA procedure was performed in case 2 with asepsis preparation and local anaesthesia. The right femoral artery was catheterised using 6F sheath (Merit Medical Systems Inc., South Jordan, Utah, USA), 5F HH1 guide catheter (Terumo Corporation, Tokyo, Japan), 6F JR3.5 catheter (Terumo Corporation, Tokyo, Japan). Subsequent tumour embolisation was done by using a 6F JR3.5 guide catheter (Terumo Corporation, Tokyo, Japan), 2.4F microcatheter (Terumo Corporation, Tokyo, Japan), 1.4F micro guidewire (Terumo Corporation, Tokyo, Japan) and particulate PVA contour 300-500 microns.
Cerebral DSA procedure in case 3 was performed with asepsis preparation and local anaesthesia, right femoral artery catheterised with 6F sheath (Merit Medical Systems Inc, South Jordan, Utah, USA), and 6F JR4 guide catheter (Terumo Corporation, Tokyo, Japan).
Cerebral DSA procedure in case 5 was performed with asepsis preparation and local anaesthesia, right femoral artery was catheterized using 6F sheath (Merit Medical Systems Inc., South Jordan, Utah, USA), 6F JR4 guide catheter (Terumo Corporation, Tokyo, Japan), and 0.038 guidewire (Terumo Corporation, Tokyo, Japan). The procedure was followed by tumour embolisation procedure; using 6F JR4 guide catheter (Merit Medical Systems Inc., South Jordan, Utah, USA), 1.8F microcatheter (Terumo Corporation, Tokyo, Japan) 1.4F micro guidewire (Terumo Corporation, Tokyo, Japan) and particulate PVA contour 300-500 microns.
The result of tumour embolisation in case 2, 3 and 4 was satisfactory, with the total disappearance of tumour blush. In case 1 and case 5, the tumour blush is still visible, although reduced to some extent, because the tumour was also received blood supply from the right internal carotid artery case 1, and the right ophthalmic artery case 5 ( Table 2 ). Within 2 to 3 days of embolisation, the patients underwent tumour resection surgery and postoperative treatment for approximately 5-6 days. All the patients were discharged with good outcome and without any complications. 
Discussion
Nasopharyngeal angiofibroma (NA) was first described in ancient times by Hippocrates (5 th century BC). NA is a rare, benign fibrovascular tumour, at the superoposterior area of the sphenopalatine foramen and is often found in young men, between 14-25 years old. It is estimated to be 0.05% of all benign Head and Neck tumours. These tumours are histopathologically benign, yet clinically destructive. The most common presenting symptoms are unilateral nasal congestion, nasopharyngeal lump and recurrent epistaxis. In the later stages, this tumour can cause facial deformity, proptosis, headache and deafness. Computed tomography (CT-Scan) and magnetic resonance imaging (MRI) is the most widely used modalities for diagnosis and evaluation of tumour growth, bone destruction and staging of angiofibroma. Also, a pre-operative angiographic procedure is performed to identify Feeding artery and to describe tumour size and location [1] , [6] , [7] . In our case series, 4 patients were aged between 14-25 and 1 patient was 61 years old, thus considered as a rare case. All patients are male. Almost all patients presented with the chief complaint of nasal congestion, difficulty breathing, epistaxis as well as mass in the nasal cavity. The diagnosis was confirmed by radiological examination in the form of cerebral and carotid MSCT angiography and digital subtraction angiography (DSA).
Surgical
resection of nasopharyngeal angiofibroma is the mainstay of treatment. Other treatment modalities include radiation, cryotherapy, electrocoagulation, hormonal therapy, embolisation and injection of sclerosing agents [8] , [9] . Although surgical excision is the definite treatment, the risk of this procedure is high, particularly due to the high risk of bleeding, since the tumour is highly vascularized. Fonseca et al. reported that there was no significant difference in bleeding risk between 15 patients who undergo surgery without preoperative embolisation and those with pre-operative embolisation [10] . Gaillard et al. reported that there could be the risk of tumour recurrence in patients who were not preoperatively embolized. Furthermore, Gaillard confirmed that cure rates could be as high as 94% if pre-operative tumour embolisation is performed [11] .
In our institution, this is the first serial cases of preoperative tumour embolisation for nasopharyngeal angiofibroma, before tumour resection was performed. Embolisation is a minimally invasive procedure, aimed at devascularization of tumour or cerebrovascular malformation. A catheter is passed through femoral, navigated until its tip is in the target vessel. In this case, the target vessel is the Feeding artery of the nasopharyngeal tumour. An embolisation agent is then ejected through the catheter tip into the blood vessel to revascularize the tumour.
In all five cases, the internal maxillary artery, a branch of the external carotid artery, is the main Feeding artery for the Nasopharyngeal Angiofibroma ( Table 2) , but there are other Feeding arteries, such as the C4 segment of the right internal carotid artery and the right ophthalmic artery. After the Feeding artery was identified, pre-operative tumour embolisation was performed using the PVA foam particle agent. PVA foam particle is routinely used as embolisation agent for preoperative embolisation. PVA can produce permanent and non-absorbing occlusion, with a low rate of blood vessel recanalisation. All five patients experienced anaemia both before and after tumour embolisation and tumour resection. All patients underwent tumour resection after the pre-operative embolisation. During the surgical procedure, the blood loss is only around 500 cc, and all patients were discharged, after 5-6 days of postoperative treatment, without any severe complications.
In conclusion, preoperative embolisation of the Feeding artery for Nasopharyngeal Angiofibroma is a very advisable procedure. Pre-operative embolisation can reduce blood loss during perioperative surgical operation and improve outcome. In our institution, we routinely perform it. Before embolisation procedure, thorough evaluation with MSCT angiography and DSA must be performed to evaluate the Feeding artery.
